Cytokinetics drug hits dual goals in genetic heart disease study
Adam Feuerstein is a senior author and biotech columnist, reporting on the crossroads of drug improvement, enterprise, Wall Street, and biotechnology. He can also be a co-host of the weekly biotech podcast The Readout Loud and creator of the e-newsletter Adam’s Biotech Scorecard. You can attain Adam on Signal at stataf.54. Cytokinetics stated Tuesday that…
